<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite the identification of Epstein-Barr virus (EBV) in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) over 40 years ago, the exact contribution of EBV to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> is undefined </plain></SENT>
<SENT sid="1" pm="."><plain>EBV encodes for multiple proteins in latent B cells that affect B cell survival and activation </plain></SENT>
<SENT sid="2" pm="."><plain>One such protein, latent membrane protein 2A (LMP2A), protects B cells from numerous pro-apoptotic stimuli </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we tested whether LMP2A protects B cells from <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induced by aberrant c-MYC expression that precedes and dominates <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We crossed LMP2A-transgenic mice (LMP2A-Tg), in which <z:hpo ids='HP_0000001'>all</z:hpo> B cells express LMP2A, to a transgenic mouse that expresses a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> translocation of myc (lambda-MYC-Tg mice) </plain></SENT>
<SENT sid="5" pm="."><plain>LMP2A promotes proliferation and protects B cells from MYC-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in lambda-MYC-Tg mice </plain></SENT>
<SENT sid="6" pm="."><plain>LMP2A also accelerates the development of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in LMP2A/lambda-MYC-Tg mice </plain></SENT>
<SENT sid="7" pm="."><plain>Finally, LMP2A increases the expression of Bcl-X(L) in both pre-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> B cells and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, suggesting a mechanism for LMP2A-mediated B cell survival in the presence of MYC </plain></SENT>
<SENT sid="8" pm="."><plain>These results support a hypothesis that EBV LMP2A promotes <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development by protecting pre-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> B cells that would normally apoptose after the c-myc translocation </plain></SENT>
</text></document>